In October, MedeAnalytics is recognizing Breast Cancer Awareness Month, a worldwide campaign to increase awareness, education and research about breast health and the importance of early detection. Breast cancer is the second most common kind of cancer in women, and one in eight women will get breast cancer in their life time. Through annual screenings like mammograms, women can survive breast cancer when it’s found and treated early.
Here’s how MedeAnalytics will recognize Breast Cancer Awareness Month:
- Our associates will be participating as a team, Mede Pirates of The Cure-Ribbean, in the Race for the Cure in Dallas on Saturday, October 26 and remote employees will be joining their local races.
- MedeAnalytics has partnered with Susan G. Komen to present a collaborative Lunch & Learn educational event hosted by Susan G. Komen ambassador Natasha Mmeje. MedeAnalytics’ employees will learn about the latest in breast cancer research and treatment resources.
- Wear Pink Wednesdays will be acknowledged throughout October to drive awareness
- Employees can share their personal stories of their loved ones and friends to show support on our internal message board
Join us as we participate in promoting this important message of hope and support.
Get our take on industry trends
MedeAnalytics at HIMSS26: Turning Insight into Measurable Healthcare Performance
March 9-12, 2026 | Venetian Convention & Expo Center | Las Vegas As margin pressure intensifies and value-based care…
Read on...Turning social risk into measurable financial performance
Payers increasingly recognize that social risk factors materially influence total cost of care, utilization, and quality performance. Yet for many…
Read on...The GLP-1 Insights Series, Part 2: Maximizing impact and savings through analytics
GLP-1s present a major opportunity for organizations to improve clinical outcomes and reduce long-term healthcare costs. However, payers and providers…
Read on...The GLP-1 Insights Series, Part 1: Long-term impact on costs and outcomes for payers and providers
Few pharmaceuticals have surged in popularity as fast as GLP-1s. This growth is well-justified. GLP-1s, a class of medications originally…
Read on...
